Market
Medtronic to acquire SPR Therapeutics for $650m
Medtronic announced an agreement to acquire SPR Therapeutics for approximately $650 million in upfront cash. The deal expands Medtronic's chronic pain treatment portfolio, adding SPR's neuromodulation and pain-management technologies to the company's existing offerings in that therapeutic area.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network